Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individual Therapy for Patients With Wilson's Disease
NCT03957720Phase 1Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Mar 2019
- Primary completion
- Dec 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of Dimaval, succimer and zinc gluconate in Wilson's disease, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: Serum ceruloplasmin at 5 years, 24-hour urine copper at 5 years and 13 more. Status: unknown.
02
Drugs
Dimavalsuccimerzinc gluconate
03
Conditions
Wilson's disease
Beyond the preview
Go deeper on NCT03957720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03957720.